Clinical Trial Update: A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines [Phase 1, Phase 2]

View source ↗

Summary

A combined Phase I/II trial evaluates recombinant Botulinum toxin type A for moderate to severe glabellar lines; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• To Severe Glabellar Lines

Drugs mentioned

• Recombinant Botulinum Toxin Type A (botulinum toxin type A)

Snippet

Sponsor: Chongqing Claruvis Pharmaceutical Co., Ltd. | Conditions: Moderate to Severe Glabellar Lines | Phase 1, Phase 2 | Status: COMPLETED